View in EDS

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Saved in:
Bibliographic Details
Title: A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Authors: Dawson MA; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huntly BJP; University of Cambridge, Cambridge, United Kingdom., Karadimitris A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Alegre A; Hospital Universitario de La Princesa and Quironsalud, Madrid, Spain., Chaidos A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Vogl DT; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Pollyea DA; University of Colorado School of Medicine, Aurora, Colorado., Davies FE; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York., Morgan GJ; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York., Glass JL; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Kamdar M; University of Colorado School of Medicine, Aurora, Colorado., Mateos MV; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain., Tovar N; Hospital Clínic, University of Barcelona, Barcelona, Spain., Yeh P; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Delgado RG; Hospital Virgen de la Victoria, Málaga, Spain., Basheer F; Addenbrooke's Hospital, Cambridge, United Kingdom., Marando L; University of Cambridge, Cambridge, United Kingdom., Gallipoli P; Addenbrooke's Hospital, Cambridge, United Kingdom., Wyce A; GSK, Collegeville, Pennsylvania., Krishnatry AS; GSK, Collegeville, Pennsylvania., Barbash O; GSK, Collegeville, Pennsylvania., Bakirtzi E; GSK, Collegeville, Pennsylvania., Ferron-Brady G; GSK, Collegeville, Pennsylvania., Karpinich NO; GSK, Collegeville, Pennsylvania., McCabe MT; GSK, Collegeville, Pennsylvania., Foley SW; GSK, Collegeville, Pennsylvania., Horner T; GSK, Collegeville, Pennsylvania., Dhar A; GSK, Collegeville, Pennsylvania., Kremer BE; GSK, Collegeville, Pennsylvania., Dickinson M; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Feb 16; Vol. 29 (4), pp. 711-722.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36350312
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dawson+MA%22">Dawson MA</searchLink>; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Borthakur+G%22">Borthakur G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Huntly+BJP%22">Huntly BJP</searchLink>; University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Karadimitris+A%22">Karadimitris A</searchLink>; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Alegre+A%22">Alegre A</searchLink>; Hospital Universitario de La Princesa and Quironsalud, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Chaidos+A%22">Chaidos A</searchLink>; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Vogl+DT%22">Vogl DT</searchLink>; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Pollyea+DA%22">Pollyea DA</searchLink>; University of Colorado School of Medicine, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Davies+FE%22">Davies FE</searchLink>; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Morgan+GJ%22">Morgan GJ</searchLink>; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Glass+JL%22">Glass JL</searchLink>; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Kamdar+M%22">Kamdar M</searchLink>; University of Colorado School of Medicine, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Tovar+N%22">Tovar N</searchLink>; Hospital Clínic, University of Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Yeh+P%22">Yeh P</searchLink>; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Delgado+RG%22">Delgado RG</searchLink>; Hospital Virgen de la Victoria, Málaga, Spain.<br /><searchLink fieldCode="AU" term="%22Basheer+F%22">Basheer F</searchLink>; Addenbrooke's Hospital, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Marando+L%22">Marando L</searchLink>; University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gallipoli+P%22">Gallipoli P</searchLink>; Addenbrooke's Hospital, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wyce+A%22">Wyce A</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Krishnatry+AS%22">Krishnatry AS</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Barbash+O%22">Barbash O</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Bakirtzi+E%22">Bakirtzi E</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Ferron-Brady+G%22">Ferron-Brady G</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Karpinich+NO%22">Karpinich NO</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22McCabe+MT%22">McCabe MT</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Foley+SW%22">Foley SW</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Horner+T%22">Horner T</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Dhar+A%22">Dhar A</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Kremer+BE%22">Kremer BE</searchLink>; GSK, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Dickinson+M%22">Dickinson M</searchLink>; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2023 Feb 16; Vol. 29 (4), pp. 711-722.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36350312
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-22-1284
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 711
    Titles:
      – TitleFull: A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dawson MA
      – PersonEntity:
          Name:
            NameFull: Borthakur G
      – PersonEntity:
          Name:
            NameFull: Huntly BJP
      – PersonEntity:
          Name:
            NameFull: Karadimitris A
      – PersonEntity:
          Name:
            NameFull: Alegre A
      – PersonEntity:
          Name:
            NameFull: Chaidos A
      – PersonEntity:
          Name:
            NameFull: Vogl DT
      – PersonEntity:
          Name:
            NameFull: Pollyea DA
      – PersonEntity:
          Name:
            NameFull: Davies FE
      – PersonEntity:
          Name:
            NameFull: Morgan GJ
      – PersonEntity:
          Name:
            NameFull: Glass JL
      – PersonEntity:
          Name:
            NameFull: Kamdar M
      – PersonEntity:
          Name:
            NameFull: Mateos MV
      – PersonEntity:
          Name:
            NameFull: Tovar N
      – PersonEntity:
          Name:
            NameFull: Yeh P
      – PersonEntity:
          Name:
            NameFull: Delgado RG
      – PersonEntity:
          Name:
            NameFull: Basheer F
      – PersonEntity:
          Name:
            NameFull: Marando L
      – PersonEntity:
          Name:
            NameFull: Gallipoli P
      – PersonEntity:
          Name:
            NameFull: Wyce A
      – PersonEntity:
          Name:
            NameFull: Krishnatry AS
      – PersonEntity:
          Name:
            NameFull: Barbash O
      – PersonEntity:
          Name:
            NameFull: Bakirtzi E
      – PersonEntity:
          Name:
            NameFull: Ferron-Brady G
      – PersonEntity:
          Name:
            NameFull: Karpinich NO
      – PersonEntity:
          Name:
            NameFull: McCabe MT
      – PersonEntity:
          Name:
            NameFull: Foley SW
      – PersonEntity:
          Name:
            NameFull: Horner T
      – PersonEntity:
          Name:
            NameFull: Dhar A
      – PersonEntity:
          Name:
            NameFull: Kremer BE
      – PersonEntity:
          Name:
            NameFull: Dickinson M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 02
              Text: 2023 Feb 16
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1